未知股票 TARO 深 沪
已收盘 06-21 16:00:00 美东时间
42.97
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 42.97
- 总市值 16.15亿
- 52周最高 --
- 市盈率 静 29.98
- 换手率 0.00%
- 52周最低 --
- 委 比 0.00%
- 总股本 3758.46万
- 历史最高 --
- 量 比 0
- 振 幅 0.00%
- 历史最低 --
- 每 手 1
- 风险率 3.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多太阳制药完成对Taro Pharmaceutical的全面收购
印度太阳制药(Sun Pharmaceutical Industries Limited)宣布成功完成Taro Pharmaceutical Industri...
2024-06-25 16:46
India-based Sun Pharmaceutical closes merger with Taro
Sun Pharmaceutical said on Monday that the India-based specialty generics company has completed its merger with the Israel-based Taro Pharmaceutical Industries (NYSE:TARO). Sun Pharma acquired all the...
2024-06-24 20:02
Taro Pharmaceutical Industries Ltd.2024财年实现净利润53.87百万美元，同比增加111.67%
3月31日，Taro Pharmaceutical Industries Ltd.（TARO.US）公布财报，公告显示公司2024财年净利润为53.87百万美元...
2024-05-21 21:18
Taro Pharmaceutical Indus(TARO.US)：2024年Q4财报实现营收1.649亿美元，前值为1.466亿美元；每股收益为0.43美元，前值为0.18美元。
Taro Pharmaceutical Indus(TARO.US)：2024年Q4财报实现营收1.649亿美元，前值为1.466亿美元；每股收益为0.43美元...
2024-05-21 05:51
IP Fights Hungers and Disaster Relief in Mexico
QUERETARO / ACCESSWIRE / March 6, 2024 / International Paper is committed to th...
2024-03-07 02:30
Kuehn Law Encourages PGTI, TAST, TARO, and ANSS Investors to Contact Law Firm
NEW YORK, Jan. 30, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may see...
2024-01-31 02:18
Earnings Scheduled For January 25, 2024
Companies Reporting Before The Bell • Nokia (NYSE:NOK) is projected to report quarterly earnings at $0.15 per share on revenue of $7.05 billion.
2024-01-25 18:51
印度Sun Pharma和Taro药业达成合并协议
印度太阳医药工业有限公司(Sun Pharma)和Taro Pharmaceutical Industries Ltd.宣布，双方已经签订了一项最终合并协议，其...
2024-01-19 15:54
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates TARO, MDC, PGTI, VIA
NEW YORK, Jan. 18, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...
2024-01-19 02:52
HC Wainwright & Co. Downgrades Taro Pharmaceutical Indus to Neutral, Maintains Price Target to $43
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Taro Pharmaceutical Indus (NYSE:TARO) from Buy to Neutral and maintains the price target from $43 to $43.
2024-01-18 19:15
